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ORIGINAL RESEARCH

Effects of Kynurenine Pathway Metabolites on Intracellular
NAD+ Synthesis and Cell Death in Human Primary Astrocytes
and Neurons
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and Gilles J. Guillemin 1,4
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Abstract: The kynurenine pathway (KP) is a major route of L-tryptophan catabolism resulting in the production of the
essential pyridine nucleotide nicotinamide adenine dinucleotide, (NAD+). Up-regulation of the KP during inflammation
leads to the release of a number of biologically active metabolites into the brain. We hypothesised that while some of the
extracellular KP metabolites may be beneficial for intracellular NAD+ synthesis and cell survival at physiological concentrations, they may contribute to neuronal and astroglial dysfunction and cell death at pathophysiological concentrations. In
this study, we found that treatment of human primary neurons and astrocytes with 3-hydroxyanthranilic acid (3-HAA),
3-hydroxykynurenine (3-HK), quinolinic acid (QUIN), and picolinic acid (PIC) at concentrations below 100 nM significantly
increased intracellular NAD+ levels compared to non-treated cells. However, a dose dependent decrease in intracellular
NAD+ levels and increased extracellular LDH activity was observed in human astrocytes and neurons treated with 3-HAA,
3-HK, QUIN and PIC at concentrations ⬎100 nM and kynurenine (KYN), at concentrations above 1 μM. Intracellular
NAD+ levels were unchanged in the presence of the neuroprotectant, kynurenic acid (KYNA), and a dose dependent increase
in intracellular NAD+ levels was observed for TRP up to 1 mM. While anthranilic acid (AA) increased intracellular NAD+
levels at concentration below 10 μM in astrocytes. NAD+ depletion and cell death was observed in AA treated neurons at
concentrations above 500 nM. Therefore, the differing responses of astrocytes and neurons to an increase in KP metabolites
should be considered when assessing KP toxicity during neuroinflammation.

Introduction

Tryptophan (TRP) catabolism via the kynurenine pathway (KP) represents the major pathway for the
synthesis of nicotinamide adenine dinucleotide (NAD+).1 Essential NAD+ dependent reactions can be
divided into three main categories:2 (1) NAD+ is an important contributor to energy (ATP) production;3
(2) NAD+ serves as a cofactor for NAD glycohydrolases involved in intracellular calcium regulation;4,5
(3) NAD+ is a substrate for the family of DNA nick sensing poly(ADP-ribose) polymerases (PARP)6–8
and the class III histone deacetylases known as sirtuins.9,10 NAD+ levels are extremely volatile and can
be significantly reduced under conditions of excessive PARP-1 activation caused by oxidative damage
to DNA, and during mitosis.11 Thus, continuous biosynthesis of NAD+ is vital to the maintenance and
ongoing cell viability of all cells.12
The KP is the principal route of L-tryptophan catabolism, resulting in the production of NAD+ (Fig. 1).
Over-activation of the KP has been implicated in the pathogenesis of several neurological disorders
including Huntington’s disease (HD), Alzheimer’s disease (AD), and the acquired immunodeficiency
syndrome (AIDS)-dementia complex.13–17 The pathway is regulated by the immune-factor responsive
enzyme indoleamine-2,3-dioxygenase (IDO) in most cells and by tryptophan-2,3 dioxygenase (TDO)
in the liver which is modulated by tryptophan and glucocorticoids.18,19
Several intermediate products of the KP are known to be neurotoxic. Among them, the N-methylD-aspartate (NMDA) receptor agonist and neurotoxin, quinolinic acid (QUIN) is likely to be most important
in terms of biological activity.15 Anthranilic acid (AA), 3-hydroxyanthranilic acid (3-HAA), and
3-hydroxykynurenine (3-HK) have been shown to generate free radicals leading to neuronal damage
similar to QUIN.15 The early upstream KP metabolite kynurenic acid (KYNA), has been shown to antagonise the
Correspondence: Gilles J. Guillemin, Department of Pharmacology, Faculty of Medicine, University of NSW,
Sydney, Australia 2052. Email: g.guillemin@cfi.unsw.edu.au
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of human neurons and astrocytes treated with
physiological and pathophysiological concentrations of TRP, KYN, KYNA, AA, 3-HAA, 3-HK,
PIC, and QUIN respectively (0.1–100 μM). Intracellular NAD+ levels were measured using the
thiazolyl blue microcycling assay. The effect of
KP metabolites on cell viability was determined
by measuring the release of lactate dehydrogenase
into the extracellular medium.

neurotoxic effects of QUIN and glutamate-mediated
NMDA receptor activation.20,21 The downstream
metabolite picolinic acid (PIC) is an endogenous
metal chelator within the brain22,23 that displays some
protection against QUIN induced toxicity and
posesses immune regulatory activity.24,25
Given the significance of intracellular NAD+
levels for the maintenance of total cell integrity
and cell viability, we used primary monocultures
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Figure 1. The Kynurenine Pathway of Tryptophan Degradation. A) Indoleamine 2,3-dioxygenase (IDO); B) Tryptophan 2,3 dioxygenase
(TDO) C) Kynurenine Formylase; D) Kynurenine-Amino Transferase; E) Kynurenine 3Hydroxylase; F) Kynureninase; G) Non-specific
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Materials and Methods
Reagents and chemicals

Dulbecco’s phosphate buffer solution (DBPS) and
all other cell culture media and supplements were
from Invitrogen (Melbourne, Australia) unless otherwise stated. Nicotinamide, bicine, β-nicotinamide
adenine dinucleotide reduced form (β-NADH),
3-[-4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT), alcohol dehydrogenase
(ADH), sodium pyruvate, TRIS, γ-globulins,
L-tryptophan (TRP), kynurenine (KYN), kynurenic
acid (KYNA), anthranilic acid (AA), 3-hydroxyanthranilic acid (3-HAA), 3-hydroxykynurenine
(3-HK), picolinic acid (PIC), and quinolinic acid
(QUIN) were obtained from Sigma-Aldrich
(Castle-Hill, Australia). Phenazine methosulfate
(PMS) was obtained from ICN Biochemicals (Ohio,
U.S.A). Bradford reagent was obtained from BioRad,
Hercules (CA, U.S.A).

Cell cultures

Human foetal brains were obtained from 16–19 week
old foetuses collected following therapeutic termination with informed consent. Mixed brain cultures
were prepared and maintained using a protocol previously described by Guillemin et al.26 Astrocytes
and neurons were prepared from the mixed brain cell
cultures, and maintained using a protocol previously
described by Guillemin et al.27

Primary brain cells and KP metabolite
culture treatments

Human primary astrocytes and neurons were
incubated with various concentrations of the KP
metabolites (0.1–100 μM) for 24 hours. Experiments
were performed with primary cultures derived from
three different human foetal brains with each individual preparation tested in triplicate.

NAD(H) Microcycling assay
for the measurement of intracellular
NAD+ concentrations

Intracellular NAD+ concentration following 24 hour
incubation with the desired concentrations of KP
metabolites were measured spectrophotometrically
using the thiazolyl blue microcycling assay established by Bernofsky and Swan28 adapted for 96 well
plate format by Grant and Kapoor.29
International Journal of Tryptophan Research 2009:2

Extracellular LDH activity
as a measurement for cytotoxicity

The release of lactate dehydrogenase (LDH) into
culture supernatant correlates with the amount of
cell death and membrane damage, providing an
accurate measure of cellular toxicity. LDH activity
following 24 hour incubation with the desired
concentrations of KP metabolites was assayed
using a standard spectrophotometric technique
described by Koh and Choi.30

Bradford protein assay
for the quantification of total protein

NAD+ concentration and extracellular LDH activity
were adjusted for variations in cell number using the
Bradford protein assay described by Bradford.31

Data analysis

Results obtained are presented as the means ± the
standard error of measurement (SEM). Significant
differences between results were verified using the
two-tailed t-test with equal variance. Differences
between treatment groups were considered significant if p was less than 0.05 (p ⬍ 0.05).

Results
Effect of extracellular KP metabolites
+
on intracellular NAD concentrations
in human astrocytes and neurons
TRP induced a dose-dependent increase in intracellular NAD + levels in both human neurons
(at ⬎100 nM TRP) and astrocytes (at ⬎500 nM
TRP), (Fig. 2). We found that 3-HAA, 3-HK, QUIN
and PIC significantly increased intracellular NAD+
levels at a low concentration of 100 nM but substantially decreased NAD+ levels at higher concentrations (Fig. 2) in both cell types. Treatment
with KYNA had no significant effect on intracellular NAD+ activity in either neuronal or astroglial
cultures (Fig. 2). A dose-dependent decrease in
intracellular NAD+ levels was observed in KYN
treated astrocytes and neurons at concentrations above 1 μM. AA increased intracellular
NAD+ levels at concentrations below 50 μM in
human astrocytes. However in human neurons
NAD+ depletion was observed at AA concentrations ⱖ500 nM for neurons and ⱖ100 μM for
astrocytes (Fig. 2).
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Figure 2. The effect of KP metabolites on intracellular NAD+ levels in human neurons and astrocytes. (Control = 0 μM treatment for each
metabolite and cell type) A) The effect of TRP (1–1000 μM) on intracellular NAD+ in human neurons and astrocytes after 24 hours. *p ⬍ 0.05
compared to control in human neurons. ¥p ⬍ 0.05 compared to control in human astrocytes. B) The effect of KYN (1–1000 μM) on intracellular
NAD+ in human neurons and astrocytes after 24 hours. *p ⬍ 0.05 compared to control in human neurons. ¥p ⬍ 0.05 compared to control in
human astrocytes. C) The effect of KYNA (1–1000 μM) on intracellular NAD+ in human neurons and astrocytes after 24 hours. *p ⬍ 0.05
compared to control in human neurons. ¥p ⬍ 0.05 compared to control in human astrocytes. D) The effect of 3-HAA (1–1000 μM) on
intracellular NAD+ in human neurons and astrocytes after 24 hours. *p ⬍ 0.05 compared to control in human neurons. ¥p ⬍ 0.05 compared
to control in human astrocytes. E) The effect of 3HK (1–1000 μM) on intracellular NAD+ in human neurons and astrocytes after 24 hours.
*p ⬍ 0.05 compared to control in human neurons. ¥p ⬍ 0.05 compared to control in human astrocytes. F) The effect of AA (1–1000 μM) on
intracellular NAD+ in human neurons and astrocytes after 24 hours. *p ⬍ 0.05 compared to control in human neurons. ¥p ⬍ 0.05 compared
to control in human astrocytes. G) The effect of QUIN (1–1000 μM) on intracellular NAD+ in human neurons and astrocytes after 24 hours.
*p ⬍ 0.05 compared control in human neurons. ¥p ⬍ 0.05 compared to control in human astrocytes. H) The effect of PIC (1–1000 μM) on
intracellular NAD+ in human neurons and astrocytes after 24 hours. *p ⬍ 0.05 compared to control in human neurons. ¥p ⬍ 0.05 compared
to control in human astrocytes. (n = 3 for each treatment group).
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Effect of extracellular KP metabolites
on extracellular LDH activity in human
astrocytes and neurons
Consistent with the results obtained for intracellular
NAD+ levels, no significant change was observed
in extracellular LDH activity for both astrocyte and
neuronal cultures treated with TRP or KYNA up to
1 mM (Fig. 3). However treatment with 3-HAA,
3-HK, QUIN and PIC increased extracellular LDH
activity at concentrations above 100 nM (Fig. 3) in
both cell types. A dose-dependent increase in extracellular LDH activity was observed in astrocytes
and neurons treated with KYN at concentrations
above 1 μM. However the magnitude of LDH
release following KYN treatment was significantly
less than that observed for any of the other toxic
metabolites. LDH activity was also increased for
cells treated with AA at concentrations above
100 nM in astrocytes and at or above 100 nM in
neurons (Fig. 3).

Discussion

Neurodegenerative diseases are often characterised
by a loss of neuronal cells in specific regions of the
brain. Given the importance of intracellular NAD+
levels for maintaining overall cellular integrity and
function, it is conceivable that reduced NAD+ levels
are a potential pathogenic mechanism for neuronal
and astroglial cell death.11,8 TRP has been used as a
supplement for some years in the United States
before being removed due to an outbreak of the lethal
autoimmune disease, eosinophilia-myalgia syndrome (EMS) resulting in 36 deaths.11 Large doses
of TRP can induce the build-up of selected white
blood cells leading to EMS. Since the KP is a major
regulator of the immune response,32 the toxic effect
may be due to inhibition of normal tolerogenic cell
T-cell death following IDO induction.11
In this study, we found that TRP supplementation produced a dose-dependent increase in intracellular NAD+ levels in human astrocytes and
neurons after 24 hours (Fig. 2). The physiological
concentration of TRP is human plasma is estimated
to be 40–90 μM.33,34 Lower serum concentrations
have been observed in several disorders including
depression and anxiety,35 rheumatoid arthritis36 and
following infection with HIV.33 TRP supplementation has been previously shown to be beneficial in
several neurological conditions, including insomnia and depression, since TRP can be used for the
synthesis of serotonin, melatonin and NAD+.11,19
International Journal of Tryptophan Research 2009:2

Moreover, under conditions of TRP depletion,
supplementation with TRP down-regulates
enzymes directing TRP to non-NAD+ dependent
pathways,19 suggesting a shift of all available TRP
catabolism to NAD+ synthesis.37 However, it is
clear that excessive TRP supplementation would
aggravate or induce autoimmune disease.11
The primary metabolite of TRP, N-formylkynurenine can be rapidly converted to KYN by the
enzyme arylamine formamidase. 38 KYN (its
physiological concentration is 1 μM) is converted
into several neurotoxic metabolites such as 3-HK
and QUIN in unstimulated human brain cells.39,14
Our data indicates that KYN causes intracellular
NAD+ depletion and reduced cell viability at greater
than physiological concentrations (Figs. 2 and 3).
Human astrocytes and microglial cells demonstrate
rapid cellular uptake of KYN. KYN has been shown
to increase QUIN production and KP enzyme
expression in human macrophages.27 The enhanced
generation of QUIN may account for the reduced
NAD+ levels and increased cytotoxicity observed
in human neurons and astrocytes at pathophysiological concentrations (Figs. 2 and 3).
KYN and the resulting metabolite, 3-HK can be
converted to AA and 3-HAA by kynureninase.15
These metabolites also provide additional substrate
for QUIN formation.40 The levels of 3-HK, AA and
3-HAA are significantly increased in the CSF of
patients with HD.41 Elevated levels have also been
reported in HIV cases associated with dementia,
infantile spasms, and hepatic encephalopathy.40
While 3-HK, AA, and 3-HAA appear less neurotoxic
than QUIN, these KP metabolites have been
previously shown to promote neuronal damage
largely through free radical formation but not NMDA
receptor activation.15 Under normal conditions, the
serum concentration of 3-HK, 3-HAA and AA has
been found to be 383 nM,42 24 nM35 and 21 nM,34
respectively. In this study, we found that 3-HK, AA
and 3-HAA supplementation resulted in neuronal
and astroglial NAD+ depletion and cell death in 24
hour cultures at micromolar concentrations (Fig. 1
and Fig. 2). These results are consistent with a previous study showing that 3-HK, 3-HAA, and AA also
induced a time-and dose-dependent increase in cell
death at micromolar concentrations (1–100 μM).41
These authors reported that the accompanying cell
death was significantly reduced by co-treatment with
catalase, suggesting that the neurotoxic effects of
3-HK may be mediated by increased hydrogen peroxide.41 3-HK can be converted to quinoneimines
65
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Figure 3. Effect of KP metabolites on extracellular LDH activity in human astrocytes and neurons (Control = 0 μM treatment for each metabolite
and cell type). A) The effect of TRP (1–1000 μM) on extracellular LDH activity in human neurons and astrocytes after 24 hours. *p ⬍ 0.05
compared to control in human neurons. ¥p ⬍ 0.05 compared to control in human astrocytes. B) The effect of KYN (1–1000 μM) on extracellular
LDH activity in human neurons and astrocytes after 24 hours. *p ⬍ 0.05 compared to control in human neurons. ¥p ⬍ 0.05 compared to control
in human astrocytes. C) The effect of KYNA (1–1000 μM) on extracellular LDH activity in human neurons and astrocytes after 24 hours. *p ⬍ 0.05
compared to control in human neurons. ¥p ⬍ 0.05 compared to control in human astrocytes. D) The effect of 3-HAA (1–1000 μM) on extracellular LDH activity in human neurons and astrocytes after 24 hours. **p ⬍ 0.05 compared to control in human neurons (n = 3 for each treatment
group). ¥p ⬍ 0.05 compared to control in human astrocytes. E) The effect of 3-HK (1–1000 μM) on extracellular LDH activity in human neurons
and astrocytes after 24 hours. *p ⬍ 0.05 compared to control in human neurons. ¥p ⬍ 0.05 compared to control in human astrocytes. F) The
effect of AA (1–1000 μM) on extracellular LDH activity in human neurons and astrocytes after 24 hours. *p ⬍ 0.05 compared to control in human
neurons. ¥p ⬍ 0.05 compared to control in human astrocytes. G) The effect of QUIN (1–1000 μM) on extracellular LDH activity in human neurons
and astrocytes after 24 hours. *p ⬍ 0.05 compared to control in human neurons. ¥p ⬍ 0.05 compared to control in human astrocytes. H) The
effect of PIC (1–1000 μM) on extracellular LDH activity in human neurons and astrocytes after 24 hours. *p ⬍ 0.05 compared to control in human
neurons. ¥p ⬍ 0.05 compared to control in human astrocytes (n = 3 for each treatment group).
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that can generate pro-oxidant intermediates, such as
hydrogen peroxide, organic and hydroxyl radicals,
during processes of autoxidation.43,44 Similarly, 3HK has been shown to potentiate QUIN toxicity in
rats, and the cytotoxic effect can be prevented using
free radical scavengers.45
Although 3-HK and 3-HAA have been shown
to be cytotoxic at high concentrations, physiological concentrations of 100 nM increased intracellular NAD+ levels by 18 and 12 per cent respectively,
with no detectable effect on extracellular LDH
activity (Figs. 1 and Fig. 2). The contribution of
3-HK and 3-HAA at these physiological concentrations to neuronal and astroglial cytotoxicity is
uncertain as micromolar concentrations appear to
produce neurotoxicity in-vitro.41,45
The observation that addition of these KP
metabolites can serve as substrate for NAD+ synthesis
at low concentrations (100–500 nM) implies that
under normal conditions, NAD+ levels may be
dependent on substrate availability.29 We propose
that astroglial and neuronal KP enzymes downstream
of QUIN may become saturated in the presence of
excess extracellular KP metabolites leading to an
accumulation of QUIN. Indeed, we have previously
demonstrated that exogenous 3-HAA substantially
increases QUIN synthesis in human foetal astrocytes
to neurotoxic levels implying saturation of downstream enzymes involved in catabolism of QUIN to
its essential metabolite, NAD+.27 Similarly, Blight
et al46 observed that treatment of 4-chloro-3hydroxyanthranilate, a synthetic inhibitor of
3-hydroxyanthranilic acid oxidase, was able to reduce
QUIN production and functional deficits following
experimental spinal cord injury in guinea pigs.
On the other hand, our results indicate a clear
dichotomy between exogenous AA effects in human
neurons and astrocytes. While AA appears neurotoxic at concentrations as low as 500 nM, AA
improved intracellular NAD+ levels in human
astrocytes by up to 10% in the 0.5 to 10 μM range
(Fig. 2). AA has been previously reported to impair
energy metabolism in the rat cerebral cortex at
micromolar concentrations, possibly through
inhibition of complex I–III activities in the mitochondrial respiratory chain.47 While the KP is fully
expressed in human neurons,48 kynurenine hydroxylase (KYN-OHase), which converts KYN to 3-HK
is absent in human foetal astrocytes.27 Consequently,
astrocytes cannot produce 3-HK.27 The KP is divided
into two parts in human astrocytes (Fig. 1), and KYN
may be converted to AA by kynureninase which then
International Journal of Tryptophan Research 2009:2

undergoes non-specific hydroxylation to form
3-HAA and may subsequently be used to form QUIN
and NAD+.27 This suggests a greater requirement for
AA as a substrate for NAD+ synthesis in human
astrocytes compared to human neurons, and AA may
become cytotoxic to both cell types in excess concentrations. These findings provide insight not only
in the differences between neurons and astrocytes,
but also for understanding how different brain cells
produce NAD+.
QUIN is an endogenous NMDA receptor agonist
involved in neuronal firing.15 The amount of QUIN
in the brain and CSF is usually less than 100 nM.
Increased brain QUIN levels (500–1000 nM) have
been observed in the CSF and serum in several
inflammatory brain diseases, including AD,49 HD,45
traumatic brain injury, AIDS dementia complex
(ADC),16 and other infections.15 QUIN has been
shown to be up-regulated in ageing and in association with senile plaques in the AD brain.50 The
results in the study are in line with previously published results highlighting the importance of QUIN
as a beneficial substrate for NAD+ synthesis at low
concentration, but a putative toxin able to induce
oligodendrocyte, neuronal, and astroglial apoptosis
at pathophysiological concentrations.49,51–53
As previously mentioned, PIC is an endogenous
metal chelator in the brain, and is an efficient chelator
for minerals such as chromium, zinc, manganese,
copper, and iron.23 Unbound (free) redox-active iron
and copper significantly increase free radical
generation and are found in abundance in the AD
brain.54 Disordered PIC metabolism may yet be found
to play a role in the pathophysiology of AD. The
physiological concentration of PIC in human serum
is thought to be between 100–400 nM.55 Elevated
PIC levels have been associated with fatal outcome
in Malawian children with cerebral malaria.56 Our
data shows that PIC can increase intracellular NAD+
levels at physiological concentrations (100 nM). This
may be partly due to its intracellular metal chelating
properties reducing the contribution of free redox
active metals in free radical generation.57
However, PIC appeared to also induce a dose
dependent decrease in intracellular NAD+ and
increase in extracellular LDH activity in both
human astrocytes and neurons. These results are
consistent with one study that observed signficant
PIC induced neurotoxicity that was associated with
both prolonged exposure time and increased glucose concentration in the culture supernatant.41
While the mechanism leading to PIC toxicity is
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not known, at high concentrations, PIC may be
causing disruption to some of the many trace metal
(Cu+, Zn++, Fe++) dependent biochemical reactions
essential for normal cell metabolism.
KYNA is a neuroprotective molecule with
antagonistic properties on both nicotinic-acetylcholine
and glutamatergic receptors at supra-physiological
concentrations.39 The tissue concentrations of KYNA
in the human brain have been estimated to be
between 0.2–1.5 μM.58,59 In our study, no significant
changes in intracellular NAD+ levels and cell
viability were observed across micromolar concentrations in both human primary astrocytes and neurons (Figs. 2 and 3). KYNA exhibits a high affinity
for the glycine-binding site of the NMDA receptor
at low concentrations, but can act on the glutamate
binding site on the NMDA receptor, and AMPA
receptors, at high micromolar concentrations.39
Decrease in KYNA levels below the threshold
needed for NMDA receptor antagonism can enhance
the vulnerability of dopaminergic neurons to excitotoxic insult.60 Moroni61 proposed that NMDA and
glutamate induced excitotoxic neuronal damage can
be ameliorated by diverting KYN metabolism to
KYNA synthesis. Likewise, supplementation with
TRP, an endogenous precursor for KYN synthesis,
may increase the levels of KYNA and therefore possibly slow down or prevent the formation of cytotoxic concentrations of QUIN.62,63
This study is the first to examine the effects of
extracellular KP metabolites on intracellular NAD+
synthesis and cell death in human primary astrocytes and neurons. While a large body of literature
is available on the toxic effects of KP metabolites
in regard to neuroinflammation, few studies have
considered the effect of these metabolites on intracellular NAD+ levels in-vitro. This study demonstrates that changes in the brain levels of certain KP
metabolites may be important mediators contributing to brain cell dysfunction in some neurological
disorders involving increased KP activation.
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